The table below shows Amneal Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$3.02B
$2.79B
$2.39B
$2.21B
$2.09B
$1.99B
Cost of revenue
$1.91B
$1.77B
$1.57B
$1.43B
$1.32B
$1.33B
Gross profit
$1.11B
$1.02B
$820.57M
$784.71M
$768.97M
$628.39M
R&D
$186.18M
$190.71M
$163.95M
$195.69M
$201.85M
$179.93M
AMRX annual revenue (10-K history)
Amneal Pharmaceuticals, Inc. reported annual revenue of $3.02B for fiscal year 2025. That is up 8.0% from $2.79B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.02B (FY 2016) to $3.02B. Figures come from the company's audited annual reports as filed with the SEC.
